The surge of 99 times! The crazy moment of the raw material phenol market has still left the drug company with a lingering fear, from 230 yuan / kg to 23,000 yuan / kg, refreshing the price record of raw materials in recent years. It is already the old-fashioned monopoly of raw materials in the pharmaceutical industry that will be the next focus of the pharmaceutical industry.

　　On October 11, the State Council issued the "Opinions on Further Improving the Supply of Stabilized Drugs for Shortage of Drugs", which clearly clarified the enforcement of law enforcement on the monopoly of raw materials and drugs.

　　The "Opinions" clarify that the most stringent standards should be investigated according to law, such as monopoly of raw materials and preparations, price violations, etc., and insist on paying attention to the investigation; criminals should be investigated according to law, and relevant responsible persons should be resolutely disposed of to form an effective shock.

　　In accordance with the "Opinions" plan, strive to stop a group of enterprises to take the initiative to correct the wrong price behavior before the end of December 2019, suspend the registration of a batch of abnormal price-up drugs, and punish a group of suspected price violations, fraudulent fraud or serious Untrustworthy enterprises have exposed a number of typical cases of abnormal price increases and monopoly, so that the excessively high price of drugs has been curbed.

　　“The price of raw materials is no longer dare to come?” Li Bin (a pseudonym), a manager of a pharmaceutical company in Hebei, told the “China Times” reporter that the production enterprises are afraid of the monopoly of raw materials and drugs, and the state is cracking down on monopolistic market behavior. It should also solve the problem of several major sources of raw material supply.

　　Raw materials have skyrocketed and negotiated with purchase prices.

　　As a powerful raw material for surgical disinfectants and aspirin, phenol is a best-selling product in the raw material market. In the past, supply and demand have been fluctuating little, and prices have been stable. Basically, several large pharmaceutical companies occupy more than 80% of the market. Share. It is easier to monopolize the market and manipulate prices. So it was staged the previous price rocket-style skyrocketing scene.

　　Another monopoly price increase of raw materials is also chlorpheniramine maleate (Pulmin). The previous price was 400 yuan/kg. After being monopolized, the price soared and soared to 23,300 yuan/kg, rising in one month. Up to 58 times.

　　In the past, small-sized and large-volume APIs were the target of monopolization by the general distributors, but this situation has gradually deteriorated. Li Bin learned that in the latest monopoly of raw material medicines, even the “glucose”, a large variety of raw materials related to nearly 5,000 drug approvals, is also listed. The general distributors are driven by the interests of large-scale raw materials to price their raw materials. Push up.

　　Raw materials have risen too fast, and pharmaceutical companies have either stopped production or raised prices. In the end, the people are paying for it. A large number of low-priced, best-selling drugs and proprietary Chinese medicines such as nitroglycerin, isoniazid tablets, compound licorice tablets, Qingfei Huayu pills, etc. all showed different increases in price, and actively controlled the reform of public hospitals nationwide, as well as quantitative purchase price negotiations. The "price reduction tide" sang the opposite.

　　In August this year, Chen Jintao, deputy director of the State Medical Insurance Bureau, said at the regular briefing of the State Council that the current price increase of drugs is that most of the price-increasing drugs have the characteristics of small market capacity and insufficient competition. They are often clinically necessary, lack of substitution, and are prone to appear. "With the lack of forced rise" situation.

　　On the other hand, some of the shortage of drugs or raw material drug production links are highly concentrated, and the distribution channels of raw material drugs are easily controlled, and monopoly control is used to achieve the purpose of illegal profit.

　　One question that needs to be resolved in front of Li Bin is: What should I do if I have already won the bid for the government procurement? If you abandon the bid after winning the bid, you will have to go to the government blacklist. This means that you have blocked the road. If you participate in the bidding, you will be limited and will not be able to take the big order. If you produce according to the original order, you will face a large loss. . Li Bin was caught in a dilemma.

　　Open a high-priced ticket, and multi-department joint crackdown on monopolistic behavior

　　Combating the monopoly of raw materials will become the next focus of the pharmaceutical industry. After the institutional reform, the State Administration of Market Supervision fulfilled the market supervision and anti-monopoly functions, and strengthened the crackdown on the monopoly of bulk drugs. So far, two high-priced drug companies have been issued for the monopoly price increase.

　　As early as the end of July 2017, the Zhejiang Provincial Price Bureau had forwarded the National Development and Reform Commission to abuse the market dominance of Zhejiang New Secco Pharmaceutical Co., Ltd. and Tianjin Handewei Pharmaceutical Co., Ltd. to sell isoniazid raw materials at unfairly high prices. And the decision to refuse to deal with the case without legal justification. The behavior of the above two companies was recognized as a "price monopoly" and was fined 443,900 yuan. However, compared with illegal income, a fine of several hundred thousand yuan does not seem to hurt the monopoly.

　　In July 2018, the State Administration of Markets received a report, reflecting that some glacial acetic acid API operators jointly raised prices, damaging the interests of downstream pharmaceutical manufacturers and patients. After receiving the report, the General Administration of Market Supervision launched an anti-monopoly investigation.

　　The survey found that from October 2017 to February 2018, as the only three glacial acetic acid producers in the market, Chengdu Huajing, Sichuan Jinshan, and Guangdong Taishan Xinning discussed the issue of joint price increases. Finally, a monopoly agreement was reached to jointly increase the sales price of glacial acetic acid bulk drug. From March 1st, the sales price of glacial acetic acid raw material drug increased from 7-9 yuan/kg to 28-33 yuan/kg, and at this price Sales.

　　As a raw material medicine, glacial acetic acid is mainly used for the production of hemodialysis concentrate for the treatment of diseases such as advanced kidney failure and uremia. The monopolistic behavior of the three companies is serious and the degree of harm is deep. On December 24, 2018, the State Administration of Markets and Regulations issued a decision on monopoly administrative punishment for glacial acetic acid bulk drugs, and issued the largest fines in the history of anti-monopoly in the pharmaceutical industry for Chengdu Huajing, Sichuan Jinshan and Guangdong Taishan Xinning. 128.33 million yuan.

　　As a raw material drug, chlorpheniramine is widely used in the production of commonly used drugs with large sales volume. In June 2018, the price of chlorpheniramine was rapidly increased in the short term, which caused some drugs to stop production and caused widespread concern in society.

　　Soon, the State Administration of Markets and Regulations investigated the relevant chlorpheniric drug companies. The investigation found that Henan Jiutian Pharmaceutical Co., Ltd. is the largest manufacturer of chlorpheniramine bulk drugs in China. Hunan Erkang Pharmaceutical Management Co., Ltd. has obtained the only import agent qualification for chlorpheniramine API since 2018. The sensitive API market has a dominant market position. Since February 2018, under the leadership of Hunan Erkang, the two companies involved in the case have jointly implemented the abuse of market dominance, resulting in a shortage of chlorpheniramine bulk drug supply, a sharp rise in prices, and some downstream manufacturers to cut production and stop production.

　　On January 2, 2019, the State Administration of Markets and Regulations issued a large anti-monopoly fine, which imposed a penalty of 12.43 million yuan on Henan Jiuitiesi Pharmaceutical Co., Ltd. and Hunan Erkang Pharmaceutical Co., Ltd., which implemented monopoly.

　　In addition to the administrative penalties that shocked the monopoly violations of APIs, let the bulk drug monopoly accept the daily regulatory system, strengthen the joint supervision and enforcement of the medical insurance bureau, the Health Care Commission, the General Administration of Market Supervision and the State Food and Drug Administration, which is also the healthy development of the API market in the future. The imperative.

　　The State Council’s "Opinions" also clearly require that the national, provincial, municipal, and county-level shortage drug monitoring networks and information direct reporting systems be improved, and that public medical institutions should be promoted to formulate and improve the shortage of drug management regulations, and to clarify the shortage of medical institutions. Analysis and evaluation, information reporting and other requirements.

　　If the price increase is unreasonable and illegal, the punishment shall be implemented according to the law; if the price increase is unreasonable but it does not constitute an illegal act, the interview urges the enterprise to take the initiative to correct it, and if necessary, adopt measures such as public exposure, suspension of the network, and disciplinary action.

　　"Some of the raw material drug manufacturers are too few, even the 'one hundred for one' situation, the monopoly price is of course very easy." Li Bin believes that if you want to fundamentally solve the industry's ills, on the one hand, you need to let go of the bulk drug manufacturers. The quantity, and the price increase caused by objective factors also need to be taken into consideration. "The price of drugs has dropped after the government price negotiations, and it is hoped that some shortage of drugs will be included in the clinical shortage list to support enterprise cost adjustment and production enthusiasm."

　　Source: China Times (www.chinatimes.net.cn) reporter Yu Na

　　Trainee Editor: Li Yannan Editor: Chen Yanpeng